• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Deep (Brain) Thoughts with Medtronic's Neuromodulation President

    Grab and Go: Examining the Thrombectomy Device Market

    Fine Print: A Discourse on Additive Manufacturing

    MPO's 2022 Medtech Industry Year in Review

    Micro Molding for Medtech Is Miniature Magic
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Regulatory
    Financial/Business
    Top News
    Coloplast Launches New Catheter in the U.S.

    Josh Ghaim and Sachin Jain Join Cue Health Board of Directors

    NAMSA Relaunches Medtech Outsourcing Solution

    Rollomatic Inc. Welcomes Joe Kane as CEO

    Alveo Technologies Announces New Executive Leadership
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Deep (Brain) Thoughts with Medtronic's Neuromodulation President

    Grab and Go: Examining the Thrombectomy Device Market

    Fine Print: A Discourse on Additive Manufacturing

    MPO's 2022 Medtech Industry Year in Review

    Micro Molding for Medtech Is Miniature Magic
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Reflections on 2022 and What’s Ahead for Medtech: MPO Sounding Board

    3 Ways to Prepare for ISO 13485/Part 820 Harmonization

    A New Home for Theranos' Elizabeth Holmes?

    Health Cost Drivers for Large Employers

    Braving Change: Facing Fears in the Midst of Major Transitions
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    Paragon Medical

    NDH Medical Inc.

    JBC Technologies

    Medbio LLC

    Arthur G. Russell Co. Inc., The
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    How Artificial Intelligence Can Combat Key Issues Impacting Healthcare

    Why Advanced Sensors Are Crucial Within Medical Pumps

    How Artificial Intelligence Could Help Prevent 80% of Chronic Diseases

    4 Ways to Use Injection Molding in Medical Device Manufacturing

    Telemedicine and Connectivity to Drive Material Innovation in the Near Future
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Paragon Medical

    NDH Medical Inc.

    JBC Technologies

    Medbio LLC

    Arthur G. Russell Co. Inc., The
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • eBook
    • Resources
    • Podcasts
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Top30

    15. Zimmer Biomet

    ...

    15. Zimmer Biomet
    Related CONTENT
    • Medical Devices Market to Top $671.49 Billion by 2027
    • Fluid Management System Market to be Worth $23.2 Billion By 2028
    • Talking Robotic Surgery with Zimmer Biomet
    • The Top 30 and M&A in 2021: What’s Next?
    • FDA OKs Medtronic's SynchroMed II Pump with Remodulin to Treat Hypertension
    07.26.18
    $7.8 Billion

    KEY EXECUTIVES:
    Bryan C. Hanson, President and CEO
    Daniel P. Florin, Exec. VP and CFO
    Aure Bruneau, Group President, Spine, CMF, Thoracic and Surgery Assisting Technology
    David A. Nolan Jr., Group President, Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle, Office Based Technologies and Zimmer Biomet Signature Solutions
    Daniel E. Williamson, Group President, Joint Reconstruction

    NO. OF EMPLOYEES: 18,200

    GLOBAL HEADQUARTERS: Warsaw, Ind.

    Though former Health and Human Services (HHS) secretary Tom Price resigned last September—following reports that he had used over a million dollars of taxpayers’ money on private jets for domestic travel and military planes for international travel—he was already the subject of controversy as early as January, when insider trading accusations against the Cabinet hopeful came to light.

    According to House records reviewed by CNN, Price had purchased anywhere from $1,001 to $15,000 of Zimmer Biomet shares in March 2016 when he was still a Georgia congressman. Less than a week after buying the shares, the Republican politician debuted the HIP Act, legislation that would have delayed a Centers for Medicare and Medicaid Services (CMS) regulation poised to impact payments for knee and hip replacements—the Comprehensive Joint Replacement (CJR) program.

    The CJR Model, as orthopedic surgeons and device manufacturers are undoubtedly aware of, was developed by CMS to support better and more efficient care for patients undergoing hip and knee replacements, the most common inpatient surgeries for Medicare beneficiaries. The model tests bundled payment and quality measurement for the episode of care associated with hip and knee replacements. It seeks to encourage hospitals, physicians, and post-acute care providers to collaborate to improve care quality and coordination from initial hospitalization to recovery. It holds participant hospitals financially accountable for the quality and cost of a CJR episode of care, and incentivizes increased care coordination.

    As a major manufacturer of knee and hip implants, analysts agreed that Zimmer Biomet would have felt a significant financial sting as a result of the CJR Model’s implementation. Deepening the ethical mire, Price’s campaign finance filings showed Zimmer Biomet’s political action committee had written his reelection committee a $1,000 check three months after the bill’s introduction.

    “It clearly has the appearance of using your influence as a congressman to your financial benefit,” Larry Noble, general counsel at the Campaign Legal Center, a watchdog group, told CNN regarding Price’s transaction. “If he believed in the bill, he should not have purchased the stock.”

    Zimmer Biomet, of course, claimed it was unaware of Price’s purchase of company stock at the time. Monica Kendrick, Zimmer Biomet’s vice president of corporate communications, further asserted in a statement that the company was not involved in the introduction of his bill to delay CMS regulations.

    “Zimmer Biomet had no knowledge of Congressman Price’s purchase of Zimmer Biomet stock. As is common practice, the Zimmer Biomet PAC regularly makes donations to various political campaigns, all of which are disclosed as required by law,” she told CBS News. “These actions are not connected. Zimmer Biomet has supported the Comprehensive Joint Replacement program developed and implemented by the Centers for Medicare and Medicaid Services. Zimmer Biomet was not involved in the Healthy Inpatient Procedures (HIP) Act, which was introduced by Congressman Price to delay CJR implementation.”


    ANALYST INSIGHTS: Zimmer Biomet has struggled to perform since the acquisition/combination of the Zimmer and Biomet organizations. It cost David Dvorak his job amid investor frustration. New CEO Bryan Hanson has his hands full as he seeks to execute. For the most part, he has been given 2018 as a “honeymoon period.” After that, stakeholders (investors, customers, and employees) expect to see positive results.

    —Dave Sheppard, Co-Founder and Principal, MedWorld Advisors



    Despite all protests, the CJR Model began implementation on April 1, 2016 and will run through Dec. 31, 2020—outlasting Price’s tenure as HHS secretary by over three years.

    Zimmer Biomet was closing the book on its own set of legal proceedings last January. A lawsuit concerned repeat Foreign Corrupt Practices Act (FCPA) violations by Zimmer Biomet or a subsidiary, in which the company engaged in and improperly recorded transactions with a prohibited Brazilian distributor. The SEC and U.S. Justice Department further stated that the company bribed Mexican customs officials to facilitate importation and smuggling of unregistered and mislabeled dental products. Biomet received similar charges for FCPA violations in 2012 prior to its acquisition by Zimmer. It then entered a deferred prosecution agreement, paying $22 million and retaining an independent compliance consultant to review its FCPA compliance program for three years.

    Although Zimmer Biomet complied with the investigation, the Justice Department noted the company failed to implement an effective compliance program and committed further violations under the 2012 agreement. “Biomet didn’t entirely learn its lesson the first time around as it continued to use a prohibited agent in Brazil and engaged in a new bribery scheme in Mexico,” Kara Brockmeyer, chief of the SEC Enforcement Division’s FCPA unit, said in a press release.

    According to The Indiana Lawyer, a settlement was finally reached in mid-January of last year, in which the Warsaw, Ind.-based musculoskeletal and dental company paid $30.5 million in criminal and civil penalties. This amounted to $17.4 million in criminal penalties, a $6.5 million SEC disgorgement, and a $6.5 million civil penalty. Zimmer Biomet will retain an independent corporate compliance monitor for three years. Zimmer Biomet’s offending indirect subsidiary, JERDS Lunexbourg Holding S.ár.l., agreed to plead guilty to a one-count criminal information.

    Zimmer Biomet’s official statement about the matter encouraged stakeholders that “the amounts to be paid were previously recorded in the company’s financial statements, and will not impact its 2017 outlook.”

    Disregarding how nice it must be for a multi million-dollar settlement to make a negligible impact on annual performance—Zimmer Biomet’s revenue in fiscal 2017 (ended Dec. 31) crawled slightly uphill 2 percent to reach $7.8 billion. The company’s late-2016 acquisition of LDR Holding Corporation, which added cervical disc replacement products to its spine business, combined with strong performance in the Asia Pacific region (5.4 percent growth to $1.2 billion), motivated a majority of the increase. All regions posted an expansion of sales, though far more modest—domestic revenue rose 1.3 percent to $4.9 billion, and EMEA sales took a small 1 percent step up to $1.7 billion.

    As has been the case for many years, the firm’s Knees business generated the most revenue of any segment with $2.7 billion in sales. However, that number is actually a slight fall—0.6 percent—from the previous year. This is primarily due to production delays in 2017 affecting Zimmer Biomet’s Warsaw North Campus facility—the production shortfall directly impacted the firm’s ability to fully meet case demand. Resultant insufficient inventory levels across Knee brands slightly dragged sales down within that business.

    The Knee business was halted from slipping further thanks to sales volume and mix growth led by the company’s Persona personalized knee system and Oxford partial knee. Though it didn’t make much impact on 2017 revenue, the Persona partial knee system was launched last September.

    The Persona partial knee was the first significant jointly developed new product for the company since Zimmer and Biomet’s combination. The latest in the firm’s portfolio of personalized and anatomically designed knee implant systems, the fixed-bearing Persona partial knee incorporates implants and instruments designed for uncompromising fit and efficiency in the OR. Global partial knee replacement experts and the ZiBRA Anatomical Modeling System were leveraged to analyze thousands of male and female bones to represent a diverse population for Persona partial’s development.

    Last June, Zimmer Biomet also revealed the X-PSI knee system, the first FDA-cleared and CE marked surgical planning system that allows patient-specific implant positioning using standard of care X-ray technology, as opposed to MRI or CT scanning. For use with the firm’s flagship total knee brands, X-PSI helps surgeons generate 3D anatomic models from X-ray images. Patient-specific instrument planning software is then used to view patient anatomy to develop a 3D customized surgical plan, which is then utilized to manufacture patient-specific guides and bone models. The X-PSI knee system is the company’s fourth patient- specific guide for its Personalized Solutions franchise.

    Zimmer Biomet’s Hips franchise rose a slight 0.6 percent with $1.9 billion in global sales. Although growth was somewhat offset by the aforementioned production delays at the company’s Warsaw North Campus facility and continued pricing pressure, strong performance in the Asia Pacific region and sales volume/mix growth led by the Taperloc Hip System, Arcos Modular Hip System, and G7 Acetabular System fostered the slight increase in total sales.

    The S.E.T. business, which includes surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products, experienced a 3.6 percent boost over the prior year to $1.7 billion despite the production shortfalls affecting the segment. Part of the increase was attributed to the acquisitions of sports medicine company Cayenne Medical and maker of deep vein thrombosis prevention products Compression Therapy Concepts, which closed in late 2016.

    Last February, the FDA approved an expanded 26-week efficacy claim for Zimmer Biomet’s single-injection viscosupplement (Gel-One Cross-linked Hyaluronate) for the treatment of osteoarthritis (OA)-related knee pain. The first low-volume viscosupplement available in a single-injection formulation for knee OA, it can be administered in a physician office setting for OA-associated knee pain patients who failed to respond to non-pharmacologic therapy, non-steroidal anti-inflammatory drugs (NSAIDs) or simple analgesics.

    A week later, further broadening the S.E.T. division’s offerings, the company released the Subchondroplasty (SCP) procedure in the EU and other countries recognizing the CE mark. A minimally invasive outpatient procedure, SCP addresses defects relating to subchondral bone marrow lesions (BMLs), which if left untreated, can lead to cartilage degeneration, limited function, pain, and a greater risk for joint deterioration. To repair chronic BMLs, the SCP procedure involves filling them with AccuFill Bone Substitute Material, a porous injectable calcium phosphate. The bone substitute is then slowly resorbed and replaced with healthy bone, repairing the defect.

    The Spine and CMF (craniomaxillofacial) segment boasted the most growth in 2017, ascending a respectable 15 percent from the previous year to $760 million in revenue. Much of this increase was provoked by the 2016 closing of the LDR Holding Corporation purchase, which established Zimmer Biomet as a strong competitor in the cervical disc replacement (CDR) market. LDR’s Mobi-C CDR device is the only FDA cleared device to treat both one- and two-level adjacent damaged cervical discs.

    The Spine business was further invigorated by last October’s U.S. launch of the Avenue T TLIF Cage. The posterior lumbar cage incorporates proprietary VerteBRIDGE plating, simplifying cage insertion and zero-profile intradiscal fixation through a direct, minimally invasive surgical approach. Avenue T completes Zimmer Biomet’s suite of lumbar cages with integrated fixation, which can now be used in every fusion approach. Sterile packaging and pre-assembly on a PEEK cartridge enables the cage and plates to be simultaneously loaded on the Inserter. Once implanted, the Impactor advances both plates at the same time, reducing implantation steps.

    Three weeks later, Zimmer Biomet launched the Vitality+ and Vital spinal fixation systems in the United States. Vitality+ consists of Vitality+ POWER for simple, controlled pedicle preparation and pedicle screw insertion, Vitality+ PSO for optimal pedicle subtraction osteotomy and vertebral column resection procedures, and Vitality+ HOOKS with an extensive array of additional fixation options. Vital is a minimized two-kit configuration that includes all pertinent instruments required for degenerative spine surgeries with a color-coded tray layout, which is particularly beneficial to surgeons and technicians with a small OR footprint.

    2017 sales for the firm’s Dental business fell 2.2 percent to $419 million, driven by restructuring of the dental organization in certain European markets. Revenue for remaining products and services, encompassed in the “Other” category, fell 2.5 percent from the previous year to $321 million.

    Under New Management
    Zimmer Biomet’s C-Suite was subject to two major transitions in 2017. Last January, former vice president of U.S. sales Robert D. Delp replaced Stuart Kleopfer as president of the Americas business. Delp was previously responsible for leading sales for the Knee, Hip, Bone Cement, Biologics, Extremities, Sports Medicine, Foot and Ankle, Surgical, and Trauma categories.

    David C. Dvorak, who had led Zimmer Biomet for 10 years as president and CEO and served the company for 16 years, announced he was stepping down last July. In the meantime, the Board appointed Senior Vice President and Chief Financial Officer (CFO) Daniel Florin as interim CEO until finding a permanent successor.

    “Serving alongside Zimmer Biomet’s employees over the past 16 years and leading the company as CEO for 10 of those years has been a privilege and a highlight of my professional career,” Dvorak said in a formal statement. Our collective efforts grew employment from approximately 3,000 in 2001 to 18,000 today and built a Fortune 500 company. I am particularly proud of what we have accomplished working together with surgeons and clinicians to help millions of patients globally improve their quality of life.”

    The company appointed former Medtronic executive vice president and Minimally Invasive Therapies Group president Bryan C. Hanson as president and CEO last December. Florin resumed his tenure as senior vice president and CFO, with Hanson officially taking the Zimmer Biomet reins Dec. 19, two weeks before the fiscal year’s close.

    “I am honored and excited to join the team at Zimmer Biomet,” Hanson proclaimed in a company statement. “I have long admired Zimmer Biomet, including its strong brand, commercial excellence and market-leading salesforce, healthy portfolio of marquee products and strong innovation pipeline. I share the company’s purpose of improving the quality of life for patients and I look forward to deeply familiarizing myself with Zimmer Biomet’s global operations to ensure we have the right foundation in place to support our customers and the patients they serve around the world, while driving sustained shareholder value.”
    Related Searches
    • legal
    • ct
    • legislation
    • human
    Suggested For You
    Medical Devices Market to Top $671.49 Billion by 2027 Medical Devices Market to Top $671.49 Billion by 2027
    Fluid Management System Market to be Worth $23.2 Billion By 2028 Fluid Management System Market to be Worth $23.2 Billion By 2028
    Talking Robotic Surgery with Zimmer Biomet Talking Robotic Surgery with Zimmer Biomet
    The Top 30 and M&A in 2021: What’s Next? The Top 30 and M&A in 2021: What’s Next?
    FDA OKs Medtronic FDA OKs Medtronic's SynchroMed II Pump with Remodulin to Treat Hypertension
    The 2018 Top 30 Global Medical Device Companies The 2018 Top 30 Global Medical Device Companies
    The 2018 Top 30 Global Medical Device Companies The 2018 Top 30 Global Medical Device Companies
    Millstone Medical Welcomes Chief Information Officer to Headquarter Facility Millstone Medical Welcomes Chief Information Officer to Headquarter Facility
    2. Johnson & Johnson 2. Johnson & Johnson
    6. Abbott Laboratories 6. Abbott Laboratories
    9. Becton, Dickinson and Company 9. Becton, Dickinson and Company
    13. Danaher Corp. 13. Danaher Corp.
    28. Hill-Rom Holdings Inc. 28. Hill-Rom Holdings Inc.
    Stoking the Corner Office Compensation Controversy Stoking the Corner Office Compensation Controversy
    Medtronic Begins Trial to Evaluate ECG Belt for Optimizing Heart Failure Therapy Medtronic Begins Trial to Evaluate ECG Belt for Optimizing Heart Failure Therapy

    Related Breaking News

    • Medical Devices Market to Top $671.49 Billion by 2027

      Medical Devices Market to Top $671.49 Billion by 2027

      Wearables and rising cases of chronic diseases will help fuel growth, industry data predicts.
      Precedence Research 09.16.21

    • Fluid Management System Market to be Worth $23.2 Billion By 2028

      Fluid Management System Market to be Worth $23.2 Billion By 2028

      North America dominated the global market for fluid management system in 2020 and will continue that dominance over the next seven years.
      Polaris Market Research 07.13.21

    • Surgical
      Talking Robotic Surgery with Zimmer Biomet

      Talking Robotic Surgery with Zimmer Biomet

      MPO's Sean Fenske speaks with Liane Teplitsky of Zimmer Biomet about the firm’s efforts in robotic surgery and its Rosa System.
      Sean Fenske, Editor-in-Chief 01.12.21


    • The Top 30 and M&A in 2021: What’s Next?

      The Top 30 and M&A in 2021: What’s Next?

      With three of the top five companies appointing new CEOs in the last year and the global pandemic eroding earnings, M&A strategies could look a lot different.
      Florence Joffroy-Black and Dave Sheppard, MedWorld Advisors 11.04.20

    • Cardiovascular
      FDA OKs Medtronic

      FDA OKs Medtronic's SynchroMed II Pump with Remodulin to Treat Hypertension

      SynchroMed II drug delivery system and cardiac catheter technologies were leveraged to deliver Remodulin.
      Medtronic 07.31.18

    Loading, Please Wait..

    Trending
    • The Future Of Biomedical Engineering Advancements
    • Cirtec Medical Corporation Acquires Precision Components Business From QMD
    • FDA Clears LiveMetric's Wearable Blood Pressure Monitoring Tech
    • A New Approach To Post-Market Surveillance
    • Philips Names New Supervisory Board Chairman
    Breaking News
    • Coloplast Launches New Catheter in the U.S.
    • Josh Ghaim and Sachin Jain Join Cue Health Board of Directors
    • NAMSA Relaunches Medtech Outsourcing Solution
    • Rollomatic Inc. Welcomes Joe Kane as CEO
    • Alveo Technologies Announces New Executive Leadership
    View Breaking News >
    CURRENT ISSUE

    November 2022

    • MPO's 2022 Year in Review
    • Fine Print: A Discourse on Additive Manufacturing
    • Grab and Go: Examining the Thrombectomy Device Market
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Dr. Ranjini Murthy Joins Azelis Americas as SVP of Commercial and Digital Excellence
    Pomegranate Extract Tied to Gut and Skin Microbiome Benefits
    Berry Health Benefits Symposium Includes Panel on Dietary Supplements
    Coatings World

    Latest Breaking News From Coatings World

    Evonik, Partners Launch PlasCO₂ Project for C4 Chemicals Production
    Masco Corporation Reaches $5 Million Milestone in Grant Program
    Arkema Partners with Research Institute to Open New Lab in France
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Coloplast Launches New Catheter in the U.S.
    Josh Ghaim and Sachin Jain Join Cue Health Board of Directors
    NAMSA Relaunches Medtech Outsourcing Solution
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer Revenues Soar to Record-Breaking $100B in 2022
    iuvo BioScience Appoints Industry Exec to Lead Lab Biz
    Seqens Opens Flagship R&D Center in Greater Boston
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    U.S. Prestige Beauty Industry Sales Revenue Grew 15% in 2022
    Personal Care Market Forecasted to Grow at CAGR of 6.4% from 2022-2027
    P&G Designs Recyclable Pump Dispenser
    Happi

    Latest Breaking News From Happi

    Nutricosmetics & Wellness Market Expected to Grow 5% by 2033
    Anastasia Beverly Hills Celebrates 25th Anniversary
    Henkel Honors Leading Suppliers During American Cleaning Institute Convention Week
    Ink World

    Latest Breaking News From Ink World

    Early-Bird Registration Opens for Print UV 2023
    Arkema Partners with Research Institute to Open Lab in France
    White Inorganic Pigments Market Worth $29.5 Billion by 2026: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    AWA to host 23rd Global Release Liner Industry Conference & Exhibition
    Color-Logic certifies Ecofoil digital labestock for cut sheet printers
    Brandywine Label Printing names Dave Rosen new president
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Ahlstrom Launches New Generation FluoroFree Technology
    Berry to Begin Production at India Healthcare Hub Early This Year
    FiltXPO to be Held in October
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Mobi-C Cervical Disc Replacement Procedures Top 200,000
    OPUM, Corflex Global Partner on Knee Assessment Technology
    ODT's Most-Read Stories This Week—Jan. 28
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Textiles are Smarter with Durak SilverPro Conductive Threads
    Arkema Partners with Research Institute to Open Lab in Mulhouse, France
    Veridos to Become Majority Shareholder in NetSeT

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login